Concerto HealthAI and Pfizer to develop new study designs using real-world evidence and AI for various cancers
Concerto HealthAI (MA, USA) and Pfizer (NY, USA) have announced the expansion of their existing collaboration, with the aim of developing new study designs for various cancers by employing real-world evidence and artificial intelligence (AI).
Concerto HealthAI (MA, USA) and Pfizer (NY, USA) have jointly announced the expansion of their existing precision oncology collaboration, with the aim of advancing use of real-world evidence and artificial intelligence (AI) for breast, lung, prostate and renal cell carcinoma cancers, to provide novel study designs and non-interventional studies.
The original collaboration, first announced in April 2019, saw Concerto HealthAI and Pfizer partner to make use of real-world data to generate actionable patient insights for Pfizer’s investigational therapies and commercialized therapeutics for the treatment of solid tumors and hematologic malignancies.
The expansion of the collaboration will see Pfizer be one of the industry adopters of eurekaHealth 3.0 – Concerto HealthAI’s real-world evidence enterprise solution – which integrates real-world data with AI-enabled tools and models.
Chris Boshoff, Chief Development Officer of Oncology at Pfizer Global Product Development, commented: “We are looking forward to expanding our collaboration with Concerto HealthAI and exploring the application of analytics to [real-world data] for generating [real-world evidence] in genitourinary cancers, a key area of our oncology strategy.”
Results from the first outcomes research investigations conducted under the collaboration are expected to be released in mid-2020.